← Back to Search

CAR T-cell Therapy

MT-101 for T-Cell Lymphoma (IMAGINE Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by Myeloid Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights

Summary

This trial tests a new treatment called MT-101 for patients with T cell Lymphoma. MT-101 is made from the patient's own blood cells, which are changed to attack cancer cells. The study will check if the treatment is safe and effective.

Eligible Conditions
  • Cell Therapy
  • Cutaneous T-Cell Lymphoma
  • Peripheral T-Cell Lymphoma
  • Mycosis Fungoides
  • Adoptive Cell Therapy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety and Tolerability of MT-101
Secondary study objectives
MT-101 cell kinetics in blood
The objective response rate
Other study objectives
Duration of response (DOR)
Overall survival (OS)
Progression free survival (PFS)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort 2 and Cohort 4Experimental Treatment1 Intervention
MT-101 preceded by conditioning (lymphodepleting) chemotherapy
Group II: Cohort 1 and Cohort 3Experimental Treatment1 Intervention
MT-101

Find a Location

Who is running the clinical trial?

Myeloid TherapeuticsLead Sponsor
2 Previous Clinical Trials
96 Total Patients Enrolled
Michele Gerber, MD, MPHStudy DirectorMyeloid Therapeutics
1 Previous Clinical Trials
48 Total Patients Enrolled

Media Library

MT-101 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05138458 — Phase 1 & 2
Cell Therapy Research Study Groups: Cohort 2 and Cohort 4, Cohort 1 and Cohort 3
Cell Therapy Clinical Trial 2023: MT-101 Highlights & Side Effects. Trial Name: NCT05138458 — Phase 1 & 2
MT-101 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05138458 — Phase 1 & 2
~0 spots leftby Nov 2024